Lastly, a fourth patient with MPNST was reclassified as having synovial sarcoma based on detecting an SS18::SSX2 fusion, leading to an evaluation for NY-ESO-1-based T-cell therapy. This evidence concerns the gene SS18 and malignant peripheral nerve sheath tumor.